Clive Graham Copley

Title: Clive Graham Copley: Innovator in Monoclonal Antibody Development

Introduction

Clive Graham Copley is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of cancer diagnosis and therapy through his innovative work on monoclonal antibodies. With a total of 3 patents to his name, Copley has established himself as a key figure in biomedical research.

Latest Patents

Copley's latest patents include a monoclonal antibody to carcinoembryonic antigen (CEA) and its therapeutic applications. The first patent describes an anti-CEA monoclonal antibody, designated 806.077, of murine origin, which is useful for diagnosing and treating cancer. The antibody's complementarity determining regions (CDRs) have specific sequences that enhance its effectiveness. The antibody can be humanized and may be conjugated with enzymes or co-stimulatory molecules to improve its therapeutic potential. The second patent also focuses on the anti-CEA monoclonal antibody 806.077, detailing its hybridoma and method of manufacture, further emphasizing its importance in cancer treatment.

Career Highlights

Throughout his career, Clive Graham Copley has worked with prominent companies such as Zeneca Limited and AstraZeneca UK Limited. His experience in these organizations has allowed him to develop and refine his expertise in monoclonal antibody research and development.

Collaborations

Copley has collaborated with notable colleagues, including Michael Derek Edge and Stephen Charles Emery. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Clive Graham Copley is a distinguished inventor whose work in monoclonal antibodies has the potential to significantly impact cancer diagnosis and therapy. His innovative patents and collaborations highlight his commitment to advancing medical science.